Constellate Proteomics measures antibody quality one molecule at a time. The company's RAYmAb platform reads a drop of unpurified cell culture, returning a titre value in about a second and a full profile of four critical attributes within a minute [Constellate Proteomics, retrieved 2026]. For biopharma teams developing monoclonal antibodies or antibody-drug conjugates, that data typically arrives in week six of a process. Constellate's bet is that putting it in week one changes the economics of the entire pipeline.
The Single-Molecule Wedge
The technical core is a patented single-molecule microscopy technique developed in TU Delft's Bionanoscience department [PERPLEXITY SONAR PRO BRIEF]. It uses total internal reflection fluorescence (TIRF) to analyze individual proteins from a crude sample, requiring only about one picogram of material. This allows the system to measure titre, glycosylation, aggregation, and charge variants simultaneously from the same, unpurified supernatant. The company claims this detects concentrations "several orders of magnitude lower" than established kit-based methods from competitors like PAIA Biotech [Constellate Proteomics, retrieved 2026]. The initial commercial wedge is analysis-as-a-service. Customers in China and Switzerland are sending samples for pilot projects, with a waiting list reported in Germany, Sweden, Spain, and the United States [imec.istart, September 2026]. The long-term product is a standalone benchtop instrument for in-house use.
An Academic Engine with Commercial Pilots
Constellate is a classic deep-tech academic spinout, founded in February 2026 by a team anchored in TU Delft research. The founding group blends deep technical and early commercial experience.
| Role | Name | Background |
|---|---|---|
| Co-founder & CEO | Carlos de Lannoy | PhD and ~10 years in single-molecule protein analysis; recipient of a €185,000 Faculty of Impact fellowship [PERPLEXITY SONAR PRO BRIEF][DealBio]. |
| Co-founder & CBO | Dennis de Beeld | Background in LC-MS and antibody analysis; commercial experience from running a consumer goods company [PERPLEXITY SONAR PRO BRIEF]. |
| Co-founder | Arian Khoshchin | MSc-level industrial pharmacy expert whose work shaped the platform's core capabilities [PERPLEXITY SONAR PRO BRIEF]. |
This academic pedigree has translated into early non-dilutive capital and recognition. The underlying work received a €200,000 Biotech Booster grant, and the company secured €150,000 in convertible financing [DealBio]. It was also named one of ten winners of the Academic Startup Competition [Academic Startup Competition, retrieved 2026]. In October 2026, Graduate Ventures, Tech Scout Venture Fund, and imec.istart joined a pre-seed round of undisclosed size [Graduate, October 2026]. The company is now preparing for a planned €1.9 million funding round in 2027 [imec.istart, September 2026].
The Scale and Integration Hurdle
The promise is clear: radically compressing a critical feedback loop in a process where time is measured in patent clocks and clinical trial schedules. The technical breakdown is straightforward. Single-molecule detection provides a multiplexed, label-free readout from a minute sample volume, bypassing the purification and separate assays that create the multi-week bottleneck. The architecture appears sound for the service model. The open questions emerge around scaling and integration.
First, the transition from a service to a shipped instrument is a well-documented gauntlet for deep-tech hardware companies. It involves manufacturing, supply chain, regulatory compliance for lab equipment, and building a field service and support organization. Second, the value proposition hinges on integrating this new data stream into existing cell-line development and process optimization workflows, which are often managed by legacy software platforms. Constellate's companion software, COSMO, is designed for data-driven CHO-cell-line development, but displacing entrenched tools requires more than superior data. It requires smooth integration and proving operational reliability at scale across different customer sites and sample types.
The early pilot interest is a strong signal, but the next twelve months will be about converting that interest into paid contracts and demonstrating the robustness needed for an enterprise sale. The planned 2027 fundraise will be a key test of that progress.
Sources
- [Constellate Proteomics, retrieved 2026] Company Website | https://www.constellate.pro/
- [PERPLEXITY SONAR PRO BRIEF] Web-grounded company brief
- [imec.istart, September 2026] Constellate Proteomics brings antibody quality into focus five weeks earlier
- [DealBio] Investor profile citing grant and fellowship amounts
- [Graduate, October 2026] New Pre-Seed Investment: Constellate Proteomics
- [Academic Startup Competition, retrieved 2026] Competition winners listing
- [TU Delft Applied Sciences, retrieved 2026] University article on the platform